Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Sofosbuvir/Daclatasvir Regimens for the Treatment of Covid-19: An Individual Patient Data Meta-Analysis Publisher Pubmed



Simmons B1 ; Wentzel H2 ; Mobarak S3 ; Eslami G3 ; Sadeghi A4 ; Ali Asgari A4 ; Abbaspour Kasgari H5 ; Tirgar Fakheri H6 ; Merat S4 ; Hill A7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Infectious Diseases, Imperial College London, London, United Kingdom
  2. 2. School of Public Health, Imperial College London, London, United Kingdom
  3. 3. Abadan Faculty of Medical Sciences, Abadan, Iran
  4. 4. Digestive Disease Research Institute, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Department of Clinical Pharmacy, School of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran
  6. 6. Gut and Liver Research Centre, Mazandaran University of Medical Sciences, Sari, Iran
  7. 7. Department of Translational Medicine, University of Liverpool, United Kingdom

Source: Journal of Antimicrobial Chemotherapy Published:2021


Abstract

Background: The combination of sofosbuvir and daclatasvir has a well-established safety profile and improves clinical outcomes in HCV patients. In silico and in vitro studies suggest that sofosbuvir/daclatasvir may show antiviral activity against SARS-CoV-2. Methods: Three clinical trials comparing sofosbuvir/daclatasvir-based regimens with a comparator in hospitalized COVID-19 patients were combined in a meta-analysis. The primary outcomes measured were clinical recovery within 14 days of randomization, time to clinical recovery and all-cause mortality. A two-step approach was used to analyse individual-level patient data. The individual trial statistics were pooled using the random-effects inverse-variance model. Results: Our search identified eight studies of which three met the inclusion criteria (n = 176 patients); two studies were randomized and one was non-randomized. Baseline characteristics were similar across treatment arms. Clinical recovery within 14 days of randomization was higher in the sofosbuvir/daclatasvir arms compared with control arms [risk ratio = 1.34 (95% CI = 1.05-1.71), P = 0.020]. Sofosbuvir/daclatasvir improves time to clinical recovery [HR = 2.04 (95% CI = 1.25-3.32), P = 0.004]. The pooled risk of all-cause mortality was significantly lower in the sofosbuvir/daclatasvir arms compared with control arms [risk ratio = 0.31 (95% CI = 0.12-0.78), P = 0.013]. Conclusions: Available evidence suggests that sofosbuvir/daclatasvir improves survival and clinical recovery in patients with moderate to severe COVID-19. However, the sample size for analysis was relatively small, one of the trials was not randomized and the designs were not standardized. These results need to be confirmed in larger randomized controlled trials. © 2021 The Author(s). Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved.
Experts (# of related papers)
Other Related Docs
10. Pharmacological Treatments of Covid-19, Pharmacological Reports (2020)
17. Introduction on Coronavirus Disease (Covid-19) Pandemic: The Global Challenge, Advances in Experimental Medicine and Biology (2021)
23. Covid-19: A Review on Treatment Strategies and Candidate Vaccines, Scientific Journal of Kurdistan University of Medical Sciences (2021)
31. A Review on Currently Available Potential Therapeutic Options for Covid-19, International Journal of General Medicine (2020)